Clinical Trial Update: Targeted Alpha Therapy Using Astatine (At-211) Against Differentiated Thyroid Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating astatine-211 targeted alpha therapy for differentiated thyroid cancer by Osaka University. The study status is COMPLETED.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Cancer

Drugs mentioned

• Astatine-211 targeted alpha therapy

Snippet

Sponsor: Osaka University | Conditions: Thyroid Cancer | Phase 1 | Status: COMPLETED